About Rubicon Genomics
Rubicon Genomics is a company based in Ann Arbor (United States) founded in 2000 was acquired by Takara Bio in December 2016. Rubicon Genomics has raised $13.04 million across 6 funding rounds from investors including Takara Bio, Broadoak Capital Partners and Research Corporation Technologies. The company has 33 employees as of December 31, 2018. Rubicon Genomics operates in a competitive market with competitors including RareCyte, Sequenta, seqWell, Paragon Genomics and Neogen, among others.
- Headquarter Ann Arbor, United States
- Employees 33 as on 31 Dec, 2018
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rubicon Genomics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$13.04 M (USD)
in 6 rounds
-
Latest Funding Round
$2 M (USD), Series B
Jul 15, 2015
-
Investors
Takara Bio
& 2 more
-
Employee Count
33
as on Dec 31, 2018
-
Acquired by
Takara Bio
(Dec 15, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Rubicon Genomics
Rubicon Genomics has successfully raised a total of $13.04M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $2 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rubicon Genomics
Rubicon Genomics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Takara Bio, Broadoak Capital Partners and Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research Corporation Technologies is engaged in licensing biomedical technologies.
|
Locked | Locked | Locked | |
|
Investment banking services are offered in the United States.
|
Locked | Locked | Locked | |
|
Developer of gene-based therapies as well as contract services for the industrial and agricultural sector
|
Locked | Locked | Locked |
Investor details for Rubicon Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rubicon Genomics
Investment portfolio details for Rubicon Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rubicon Genomics
Detailed financials for Rubicon Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rubicon Genomics Comparisons
Peer comparison for Rubicon Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rubicon Genomics
Rubicon Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RareCyte, Sequenta, seqWell, Paragon Genomics and Neogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| Locked | Locked | Locked |
NGS-based reagents and kits are supplied for life sciences research.
|
|
| Locked | Locked | Locked |
Provider of technologies and solutions genomic research and precision medicine
|
|
| Locked | Locked | Locked |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
|
| Locked | Locked | Locked |
Molecular biology reagents and services are supplied to biotech industries.
|
Detailed competitors of Rubicon Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rubicon Genomics
Complete news archive for Rubicon Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rubicon Genomics
Rubicon Genomics was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Rubicon Genomics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Rubicon Genomics is a funded company, having raised a total of $13.04M across 6 funding rounds to date.
As of Dec 31, 2018, the latest employee count at Rubicon Genomics is 33.
Rubicon Genomics was founded in 2000 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where reagents and kits for pre-analytical amplification technologies are developed. Three kits are offered for use with Illumina next-generation sequencing systems, while two kits support microarray and PCR applications. These products facilitate sample preparation in genomic research environments.
Rubicon Genomics's top competitors include Neogen, Paragon Genomics and Biotangents.
Rubicon Genomics has 3 investors. Key investors include Takara Bio, Broadoak Capital Partners, and Research Corporation Technologies.